Skip to main content
Not sure where to start? Get matched →
All answers

Anti-Aging · Reference

CJC-1295 vs Hexarelin: Two Receptors, Two Evidence Records, and Which One Fits

This page explains each on its own terms, puts them side by side, covers the human data, the desensitisation question, where each stands with the FDA, how each is dosed at Pepti, what each costs, and who tends to suit which.

Hexarelin (Injectable)
Hexarelin$209/mo

CJC-1295 and hexarelin both prompt the pituitary to release growth hormone, but they work through different receptors and behave differently. CJC-1295 is a modified growth-hormone-releasing hormone (GHRH) analogue; the no-DAC form compounded today lasts about half an hour and is almost always paired with ipamorelin. Hexarelin is a six-amino-acid ghrelin-receptor agonist, one of the most potent growth hormone releasers studied in people, which also raises cortisol and prolactin with each dose and loses some of its effect with continuous use. At Pepti, CJC-1295 comes as CJC-1295 / Ipamorelin; hexarelin is a single-agent vial. Both are compounded prescriptions, and neither is FDA approved.

This page explains each on its own terms, puts them side by side, covers the human data, the desensitisation question, where each stands with the FDA, how each is dosed at Pepti, what each costs, and who tends to suit which.

CJC-1295 vs Hexarelin

The short answer

If your main goal is The usual prescription What is in it Price
A daily growth hormone pulse with a clean hormonal profile CJC-1295 / Ipamorelin 6 mg CJC-1295, 12 mg ipamorelin in 5 mL $239/mo
The strongest single-agent ghrelin-receptor pulse, on a schedule with breaks Hexarelin 12.5 mg hexarelin in 5 mL $209/mo
A shorter GHRH signal with the same partner Ipamorelin + Sermorelin Sermorelin and ipamorelin in one vial $219/mo
A ghrelin-receptor pulse without the cortisol and prolactin rise Ipamorelin 5 mg ipamorelin in 5 mL $239/mo
Sleep as the main goal SERENITY Blend DSIP, Selank, CJC-1295, ipamorelin $279/mo

Every figure is an all-in monthly price covering the medication, physician review, refill management and shipping. There is no separate membership fee, and Pepti is cash-pay and does not bill insurance. Current pricing always lives on each product page.

CJC-1295 vs Hexarelin

CJC-1295 on its own terms

  • What it is

    GHRH is the signal the hypothalamus sends to tell the pituitary to release growth hormone. Its first 29 amino acids are the smallest fragment with full activity; that fragment is sermorelin. CJC-1295 is the same 29-amino-acid chain with four substitutions that protect it from the enzyme DPP-IV, described in a 2005 Endocrinology paper. It exists in two forms. The DAC form carries a "drug affinity complex" that binds albumin and keeps it circulating for days. The form compounded in blends, including Pepti's, is CJC-1295 without DAC, also called modified GRF (1-29), which lasts roughly half an hour. The forms are compared in CJC-1295 with DAC vs without DAC.

  • How it is described to work

    CJC-1295 binds the GHRH receptor on pituitary somatotroph cells, raising cyclic AMP and driving both release of stored growth hormone and synthesis of more. A 2006 American Journal of Physiology study reported once-daily CJC-1295 normalizing growth in mice engineered to lack GHRH. It contains no growth hormone; the pituitary keeps control, with somatostatin and IGF-1 feedback still in place.

  • Why it is paired with ipamorelin

    Ipamorelin acts at a different receptor on the same pituitary cells, the ghrelin receptor (GHS-R1a). A 1998 European Journal of Endocrinology paper called it "the first selective growth hormone secretagogue" because, in animal models, it released growth hormone without raising ACTH, cortisol or prolactin. GHRH-type and ghrelin-type signals are described as more than additive, so one dose of both is intended to produce a single fuller pulse. The full reference is at what is CJC-1295 / Ipamorelin.

  • What human data exists for CJC-1295

    The human data is for the DAC form. A 2006 Journal of Clinical Endocrinology and Metabolism study in healthy adults reported growth hormone rising two- to ten-fold for six days or more and IGF-1 rising for nine to eleven days after one injection, with a companion paper reporting that pulses were preserved. The no-DAC form has no human trials of its own. No trial of either form has measured sleep, recovery or body composition.

CJC-1295 vs Hexarelin

Hexarelin on its own terms

  • What it is

    Hexarelin is a synthetic hexapeptide, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, designed in the early 1990s as a more stable and more potent analogue of GHRP-6. Two of its amino acids are unnatural D-forms, which let it survive in the body. It imitates ghrelin, the stomach hormone that signals hunger and tells the pituitary to release growth hormone. It contains no growth hormone. The full reference is at what is hexarelin.

  • How it is described to work

    • The ghrelin receptor. Hexarelin binds GHS-R1a and triggers a pulse of growth hormone. A 2001 study gave healthy young men ghrelin, hexarelin and GHRH on separate days: ghrelin released the most, hexarelin the next most, GHRH the least.
    • Cortisol and prolactin. Unlike ipamorelin, hexarelin also stimulates the pituitary cells that make ACTH and prolactin. A 1997 Peptides study reported the ACTH and cortisol response being similar in size to that from corticotropin-releasing hormone.
    • The heart. Hexarelin also binds CD36, a receptor on heart muscle cells. Three small single intravenous dose studies from Turin reported a short-lived rise in ejection fraction, and rodent work describes reduced cardiac fibrosis. It is not a heart medication.
  • What human data exists for hexarelin

    More than for almost any other compounded peptide, nearly all from 1994 to 2003: single-dose pharmacology in hundreds of adults and children, two small open-label courses in short children, three single-dose cardiac studies, and one sixteen-week study of twice-daily subcutaneous hexarelin in healthy elderly adults. That sixteen-week study found no significant change in IGF-1, body fat, lean mass or bone density. There are no randomized controlled trials of hexarelin for sleep, recovery, body composition or any wellness use.

CJC-1295 vs Hexarelin

Head to head

CJC-1295 (no DAC) Hexarelin
Class GHRH analogue Ghrelin-receptor agonist (GHRP)
Receptor GHRH receptor GHS-R1a, plus CD36 on heart tissue
Length 29 amino acids 6 amino acids
Duration Roughly half an hour A pulse within the hour, gone by morning
Effect on cortisol and prolactin Not described Transient rise with each dose
Desensitisation Not a described feature Partial and reversible with continuous dosing
Appetite Not described; its usual partner ipamorelin can raise hunger Hunger after a dose is reported
Human data DAC-form pharmacokinetic trials (2006) Large 1990s pharmacology record; one sixteen-week study found no body-composition change
Outcome trials (sleep, recovery, body composition) None None positive
How Pepti supplies it With ipamorelin, in CJC-1295 / Ipamorelin and several blends Single-agent vial
Typical directions 0.25 mL once daily, Monday through Friday, on an empty stomach 0.25 mL Monday through Friday nights at bedtime
Doses per vial 20 20
Formats at Pepti Vial, or pre-filled Pen Vial only
Price at Pepti $239 a month (with ipamorelin) $209 a month

The real difference is selectivity and fade, not strength

People often ask which is "stronger." Hexarelin produced a larger single-dose growth hormone response than GHRH in the 1990s human studies, but a bigger pulse is not the whole story. Hexarelin's pulse comes with a rise in cortisol and prolactin, and its response falls with continuous use. CJC-1295 is a different signal at a different receptor, and the prescribed form is short-acting and usually paired with ipamorelin precisely so that each dose gives one clean pulse. No study has compared CJC-1295 with hexarelin directly.

The desensitisation question

In a 1998 Journal of Clinical Endocrinology and Metabolism study, healthy elderly adults took twice-daily subcutaneous hexarelin for sixteen weeks. The growth hormone response to a test dose fell by about a third by week one and by nearly half by week sixteen, and returned to baseline four weeks after stopping. Shorter intermittent schedules in older adults did not show desensitisation. That is the rationale for Pepti's five-nights-on, two-off hexarelin schedule. Desensitisation is not a described feature of CJC-1295 in the same way, which is one reason a GHRH-plus-ipamorelin pairing is the more usual choice for a course that runs uninterrupted.

CJC-1295 vs Hexarelin

Who suits which

  • CJC-1295 / Ipamorelin

    The more common prescription when the goal is a daily growth hormone pulse with the cleanest hormonal profile available: a GHRH signal plus a selective ghrelin-receptor signal, without the cortisol and prolactin rise. Prescribers who want a course that runs uninterrupted usually start here.

  • Hexarelin

    A physician's choice when the strongest single-agent ghrelin-receptor pulse is the priority, the person understands it raises cortisol and prolactin transiently, and the course is structured with breaks around the desensitisation data. It is not the first choice for people with conditions sensitive to cortisol or prolactin.

  • Can you take CJC-1295 and hexarelin together?

    The human data show a ghrelin-type peptide and a GHRH analogue producing more growth hormone together than either alone, so the general pairing is pharmacologically sound. But Pepti's CJC-1295 already comes with ipamorelin, which acts at the same receptor as hexarelin, and in the 2001 study hexarelin and ghrelin did not add to each other, which is what you would expect from two ligands for one receptor. Adding hexarelin to CJC-1295 / Ipamorelin would mean two ghrelin-receptor agonists at once, and no study informs that. Whether anything is combined is set by your physician after reviewing your intake.

CJC-1295 vs Hexarelin

When neither is the right first step

Situation What makes more sense
Possible growth hormone deficiency A diagnosis with its own testing and an FDA-approved treatment; an endocrinologist's conversation
Visceral fat specifically Tesamorelin, the GHRH analogue with randomized human trials on abdominal fat
Weight is the goal Semaglutide or tirzepatide, which have large randomized trials
Sleep is the only goal DSIP, aimed at sleep more directly
A soft-tissue injury BPC-157 or TB-500; secretagogues are not injury treatments

CJC-1295 vs Hexarelin

Where each stands with the FDA

CJC-1295 Hexarelin
503A Category 2 Placed there in 2023; removed in September 2024 when nominations were withdrawn Never placed in any category
Advisory committee 4 December 2024: voted 0 to 13 against the free base, 1 to 12 against the acetate, and against each DAC form Never reviewed
Interim list, 14 May 2026 In no category Not listed
Final FDA determination Pending None made

A committee vote is a recommendation, not a ban, and it evaluated CJC-1295 for growth hormone deficiency against the approved drugs that already exist for it. Ipamorelin, CJC-1295's partner, had a similar committee vote against it in October 2024 with no final determination. Hexarelin has simply never been taken up by the FDA either way. Both remain legal to prescribe and dispense as compounded medications. Compounded medications are not FDA approved, and neither CJC-1295 nor hexarelin is an FDA-approved drug. Are peptides FDA approved explains the difference.

CJC-1295 vs Hexarelin

Dosing, side by side

CJC-1295 / Ipamorelin Hexarelin
Printed direction Inject 0.25 mL (25 units) subcutaneously once daily Monday through Friday on an empty stomach Inject 0.25 mL (25 units) subcutaneously Monday through Friday nights at bedtime
Concentration CJC-1295 1.2 mg/mL, ipamorelin 2.4 mg/mL 2.5 mg/mL
Per dose (math from the label) 0.3 mg CJC-1295 and 0.6 mg ipamorelin 0.625 mg hexarelin
Doses per vial 20 20
Time per vial 4 weeks 4 weeks

Both are injected under the skin (subcutaneously) into the abdomen or thigh, rotating sites. The empty-stomach instruction on CJC-1295 / Ipamorelin matters because glucose and fatty acids after a meal blunt the growth hormone pulse; many prescribers direct it at bedtime. Hexarelin's bedtime timing lands its pulse on top of the natural nocturnal release, and food intake was reported in 2000 to modulate its response. You do not need to calculate anything: your directions are printed on the vial, and your physician sets them after reviewing your intake. Refills run every 28 days, one vial per fill. Vials are multi-dose solutions shipped ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. CJC-1295 / Ipamorelin also comes as a 3 mL pre-filled Pen cartridge containing 1.5 mg CJC-1295 and 6 mg ipamorelin, with Pen directions printed separately.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

CJC-1295 vs Hexarelin

Side effects

CJC-1295 / Ipamorelin. In the 2006 CJC-1295 trials, injection-site reactions and headache were the main complaints. Reported clinically: injection-site redness or soreness, a brief flush after injecting, headache, and, with the growth hormone rise, water retention or tingling in the hands, which usually settle. Some people notice hunger after a dose.

Hexarelin. Single doses were consistently reported as well tolerated in the 1990s studies. Reported clinically: warmth or flushing after the injection, hunger, a transient headache, light-headedness, and injection-site redness or soreness. Each dose also raises cortisol and prolactin for an hour or two, and a single dose produced a short-lived rise in the heart's contractility in every human study that looked, so a cardiac diagnosis belongs on the intake.

For both, growth hormone opposes insulin, so blood glucose can drift up, and anything that raises growth hormone and IGF-1 carries the class concerns of glucose intolerance, fluid retention and a theoretical concern about existing tumours. There is no established interaction list for either. Stop and contact your physician for any reaction that is severe or spreading. Swelling of the face, lips or throat, a widespread rash or difficulty breathing needs emergency care first: call 911, then tell your care team. More in is CJC-1295 / Ipamorelin safe.

CJC-1295 vs Hexarelin

Who should not take either, or should discuss it first

Situation Why
Personal history of cancer The growth hormone and IGF-1 axis supports tissue growth
Diabetes or impaired glucose tolerance Growth hormone reduces insulin sensitivity
A cardiac diagnosis Especially for hexarelin, given its direct heart effect
Conditions sensitive to cortisol or prolactin Especially for hexarelin, which raises both with each dose
Pregnancy or breastfeeding Not used; safety data is absent
Tested athletes WADA prohibits GHRH analogues and growth hormone secretagogues at all times

CJC-1295 vs Hexarelin

What the evidence shows, honestly

Both reliably raise growth hormone in people; that much is established. Beyond that, the evidence is thin for both. CJC-1295's human data is pharmacokinetic and for the DAC form, not the form prescribed today. Hexarelin's human record is deep but old, almost all single-dose pharmacology, and the one sustained subcutaneous course in adults found no change in body composition. Neither has a trial showing better sleep, recovery or body composition, and no study has compared them. Physicians prescribe both on pharmacology plus clinical experience. The honest framing is "known to raise growth hormone in humans; benefits beyond that are inferred," not "shown to work." The wider class is compared in CJC-1295 vs sermorelin and peptides vs HGH.

CJC-1295 vs Hexarelin

Where to get CJC-1295 or hexarelin prescribed

Neither can be bought legitimately without a prescription. Sites selling them "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested. The prescription route:

  1. Complete a free online intake covering your history, medications and what you want help with.
  2. A physician licensed in your state reviews it, usually within 24 hours.
  3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
  4. It ships refrigerated with your directions printed on the vial.
  5. Your physician stays reachable for questions and dose changes.

Pepti prescribes both in every state except Oklahoma, plus DC Step-by-step pages: how to get CJC-1295 / Ipamorelin prescribed online and how to get hexarelin prescribed online.

References

What this is based on.

References

  1. Ghigo E, Arvat E, Gianotti L et al.. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man · J Clin Endocrinol Metab (1994) · PMID 8126144
  2. Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy · J Clin Endocrinol Metab (1998) · PMID 9589671
  3. Rahim A, Shalet SM. Does desensitization to hexarelin occur? · Growth Horm IGF Res (1998) · PMID 10990150
  4. Ghigo E, Arvat E, Gianotti L et al.. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging · Eur J Endocrinol (1996) · PMID 8921821
  5. Klinger B, Silbergeld A, Deghenghi R et al.. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children · Eur J Endocrinol (1996) · PMID 8766941
  6. Laron Z, Frenkel J, Deghenghi R et al.. Intranasal administration of the GHRP hexarelin accelerates growth in short children · Clin Endocrinol (Oxf) (1995) · PMID 8548949
  7. Loche S, Cambiaso P, Carta D et al.. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects · J Clin Endocrinol Metab (1995) · PMID 7852535
  8. Massoud AF, Hindmarsh PC, Matthews DR, Brook CG. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity · Clin Endocrinol (Oxf) (1996) · PMID 8762732
  9. Maccario M, Veldhuis JD, Broglio F et al.. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans · Eur J Endocrinol (2002) · PMID 11888836
  10. Arvat E, di Vito L, Maccagno B et al.. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH · Peptides (1997) · PMID 9285939
  11. Ghigo E, Arvat E, Ramunni J et al.. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome · J Clin Endocrinol Metab (1997) · PMID 9253314
  12. Arvat E, Ramunni J, Bellone J et al.. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations · Eur J Endocrinol (1997) · PMID 9437229

Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.

Common questions

CJC-1295 vs Hexarelin, answered.

Hexarelin produced a larger single-dose growth hormone response than GHRH in the 1990s human studies, but it works at a different receptor, raises cortisol and prolactin, and fades with continuous use. No study has compared it with CJC-1295, and a bigger pulse has not been shown to mean a better outcome.

Next step

See what a physician recommends for you.

A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.